Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Pedro-Botet

Showing results (81-90 of 240) with videos related to

Pageof 24
Sort By:
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|March 8, 2016
[Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study]Juan Pedro-Botet, Vivencio Barrios, Vicente Pascual, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 3, 2014
[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis]Carlos Lahoz, José María Mostaza, Xavier Pintó, et al.
Medicina Clinica|March 25, 2011
[Residual lipid profile in recurrent ischemic cardiopathy]Jesús Millán, Juan Pedro-Botet, Anna Muñoz, et al.
The Journal of Laboratory and Clinical Medicine|April 11, 2002
Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart diseaseSilvia Martín, Juan Pedro-Botet, Jorge Joven, et al.
Lipids|May 8, 2018
Previous Gestational Diabetes Increases Atherogenic Dyslipidemia in Subsequent Pregnancy and PostpartumMontserrat Prados, Juana A Flores-Le Roux, David Benaiges, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|April 16, 2020
Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis SocietyJuan F Ascaso, Jesús Millán, Antonio Hernández-Mijares, et al.
Endocrinologia, Diabetes Y Nutricion|October 13, 2018
Gestational diabetes mellitus in a multiethnic population in Spain: Incidence and factors associated to impaired glucose tolerance one year after deliveryMontserrat Prados, Juana A Flores-Le Roux, David Benaiges, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 17, 2021
Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national surveyCarlos Guijarro, Fernando Civeira, José López-Miranda, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|February 11, 2020
Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemiasJuan Pedro-Botet, Juan F Ascaso, Mariano Blasco, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|January 25, 2020
Morbid obesity and dyslipidaemia: The impact of bariatric surgeryElisenda Climent, David Benaiges, Albert Goday, et al.
Pageof 24

Showing results (81-90 of 240) with videos related to

Sort By:
Pageof 24
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|March 8, 2016
[Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study]Juan Pedro-Botet, Vivencio Barrios, Vicente Pascual, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 3, 2014
[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis]Carlos Lahoz, José María Mostaza, Xavier Pintó, et al.
Medicina Clinica|March 25, 2011
[Residual lipid profile in recurrent ischemic cardiopathy]Jesús Millán, Juan Pedro-Botet, Anna Muñoz, et al.
The Journal of Laboratory and Clinical Medicine|April 11, 2002
Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart diseaseSilvia Martín, Juan Pedro-Botet, Jorge Joven, et al.
Lipids|May 8, 2018
Previous Gestational Diabetes Increases Atherogenic Dyslipidemia in Subsequent Pregnancy and PostpartumMontserrat Prados, Juana A Flores-Le Roux, David Benaiges, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|April 16, 2020
Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis SocietyJuan F Ascaso, Jesús Millán, Antonio Hernández-Mijares, et al.
Endocrinologia, Diabetes Y Nutricion|October 13, 2018
Gestational diabetes mellitus in a multiethnic population in Spain: Incidence and factors associated to impaired glucose tolerance one year after deliveryMontserrat Prados, Juana A Flores-Le Roux, David Benaiges, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 17, 2021
Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national surveyCarlos Guijarro, Fernando Civeira, José López-Miranda, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|February 11, 2020
Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemiasJuan Pedro-Botet, Juan F Ascaso, Mariano Blasco, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|January 25, 2020
Morbid obesity and dyslipidaemia: The impact of bariatric surgeryElisenda Climent, David Benaiges, Albert Goday, et al.
Pageof 24